HOT TICKET ITEM(S) <----- PLURAL UP AND COMING FOR LBTT.

THEY ARE HARD UP FOR MONEY AND HAVE ISSUED MORE STOCK TO RAISE MORE CAPITAL.

NOW WITH SUCH OUTSTANDING SHARES, LONG TERM OUTLOOK IS NOT GOOD IF YOU THINK THIS STOCK WILL SOAR TO THE $5-$25 RANGE WITHOUT A REVERSE SPLIT. TONY IS ABSOLUTELY CORRECT ABOUT THIS.

THE CURRENT PRODUCT(S) <----- PLURAL AGAIN ARE A DEFINITE HIT. MOOSE IS ABSOLUTELY CORRECT ABOUT THIS.

$2.50-$3.50 IS A REASONABLE EXPECTATION FOR THIS STOCK TO GET OUT AT THAT POINT. LOW ENOUGH TO NOT NEED A REVERSE AND NOT SO HIGH THEY HIT THEIR CEILING.

MONDAY (YESTERDAY) WAS A GOOD DAY FOR LBTT BUT I SEE A DECLINE BACK DOWN WHICH IS A GOOD THING FOR THOSE WHO NEED A FEW HUNDRED THOUSAND SHARES FOR $5,000. I THINK WITH THE CE MARK APPLICATION PROCESS, 6+ MONTHS WILL BE THE TIME FRAME. NOT SURE ABOUT HOW LONG THE TIME FRAME IS FOR THE SHOT UP TO $2.50/RANGE AND I'LL TAKE A WAIT AND SEE ATTITUDE ABOUT MY FEELINGS ON THIS ONE.

DO REMEMBER, MOST RECENTLY HEALTHSOUTH (HLSH) SHOT UP FROM .08 TO $3.25 IN LESS THAN 90-DAYS. ABOUT 4 MONTHS AGO!

PLEASE FEEL FREE TO CORRECT ME IF I'M INCORRECT IN ANY AREA SINCE I LIKE TO BE PROVEN WRONG EXCEPT FOR THE FACT, FACT FACT FACT THIS STOCK WILL SOAR!

U4---I'm not looking for $5-$25, I'll definitly be happy with $1, and a R/S would most likely be needed to get up to $5+

Also, they are expecting CE mark approval anytime now...they predicted a Late-fall 2003 date.
-----
According to Jonathan Reeves, Vice President of Operations every effort is being made to meet a “mid-fall” deadline for obtaining a CE mark for the Nipple Scope™ and begin introduction of the Nipple Scope™ at several important medical meetings in Europe and the US. Reeves added, “I think the major introduction of this exciting new product will take place at Europe’s major medical meeting in Hamburg, Germany, were Dr. Mokbel will being presenting a clinical paper concerning his experience in using the scope.”
----

Taking a look at the charts, it looks pretty good for this breakout to continue. Macd on the rise again, momo is good, and the stochastic is crossing 65, which, in an overbought situtation identifies the price is about to explode.

all IMO on my DD

-----E-mail from LBTT MR. HOLMES

In my previous email, responding to yours dated 11/14/03, I did not address all of your questions. I'll attempt to do so now.

The CE mark filing is on schedule for early this December.

We have not secured financing, though our efforts continue. It seems we have several promising opportunities.

Concerning a reverse-split in the next 12 months. Though we currently do not anticipate a reverse, near term, it is extremely difficult to predict the next twelve months. There are numerous undefined factors that could impact a decision, not the least of which could be the financing terms that may be required once a funding source has been determined.

About the FDA, our First Warning System will require a PreMarkeing Approval (PMA.) However, before we can approach the FDA, we need to complete our clinical trials. We are currently working to reduce the False Positives, an outcome of our Argentinean work. Once we have a satisfactory solution we anticipate proceeding with the clinical trials. The best estimate we have at this time, the clinical trials and their results being submitted to the FDA could take approximately 18 to 24 months to complete. While we feel we will be successful at FDA clearance of our PMA.... there is no guarantee.

Concerning our other two women's cancer products.... The Nipplescope and the O-scope, these products, for the US market require a 510K. We are acquiring a 510K for the Nipplescope. We believe, but have not confirmed, that the O-scope is covered by a predicate device.

The CE we're filing this December covers the Nipplescope for marketing in Europe and in most Asian countries, particularly, China. We're hopeful and it is quite possible we'll be introducing the Nipplescope to the US market sometime in 2004

I hope this information, while much of it tentative, is helpful in addressing your questions.

Best regards and thanks for your interest in Lifeline Biotech.

Jim Holmes, CEO
-----

Tony

RENO, Nev.--(BUSINESS WIRE)--Feb. 9, 2004--Jim Holmes, CEO, Lifeline BioTechnologies Inc. (OTC: LBTT), today announced that Advanced Biomedical Concepts has been retained to assist in the introduction of its cutting-edge Mammoscope product line to the European market.

Advanced Biomedical Concepts is headed by Carlo Micheletti, who will be responsible for providing Lifeline with markets analysis, distribution channels, distributors, sales programs and promotions. Micheletti will recommend the countries for early introduction of this product line which can assist in reducing the number of breast surgeries for women experiencing nipple discharge.

Micheletti's experience in international sales of medical products includes having established distributorships in Europe, Latin America, Australia, Asia, Mexico and Canada. He has started sales organizations in Mexico and Argentina. He was formerly with Stryker Corp.(NYSE:SYK) directing operations of sales and marketing organizations for 21 distributorships for medical products including surgical instruments, orthopedic implants and endoscopy systems.

William Reeves, Lifeline's founder and president, said, "We are pleased and excited to have the caliber of experience Mr. Micheletti provides in areas the company needs in order to have an effective introduction and sales growth of the Mammoscope product line in the European market."

Micheletti, together with company representatives, are scheduled to attend the European Breast Cancer's Fourth Annual Conference in Hamburg, Germany, March 16-20, 2004. Lifeline will be featuring its Mammoscope and related products at the conference. Reeves noted that this conference will be attended by breast cancer specialists from all over the world. Holmes noted that he had received inquiries from Southeast Asia and China who have indicated they will be attending the conference and look forward to learning more about the Mammoscope.

Holmes noted that the company's efforts continue for FDA clearance for marketing the Mammoscope in the United States, and we are optimistic of a favorable development soon.

Lifeline's Web site address: www.lbti.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe," "expects," "projects," "forecasts," "intends," "will," "anticipated," "could" or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

quote:

---

Originally posted by dawn0304:
Lifeline Prepares for the Introduction of Its Mammoscope Product Line to European Markets, Retains Marketing and Sales Firm

RENO, Nev.--(BUSINESS WIRE)--Feb. 9, 2004--Jim Holmes, CEO, Lifeline BioTechnologies Inc. (OTC: LBTT), today announced that Advanced Biomedical Concepts has been retained to assist in the introduction of its cutting-edge Mammoscope product line to the European market.

Advanced Biomedical Concepts is headed by Carlo Micheletti, who will be responsible for providing Lifeline with markets analysis, distribution channels, distributors, sales programs and promotions. Micheletti will recommend the countries for early introduction of this product line which can assist in reducing the number of breast surgeries for women experiencing nipple discharge.

Micheletti's experience in international sales of medical products includes having established distributorships in Europe, Latin America, Australia, Asia, Mexico and Canada. He has started sales organizations in Mexico and Argentina. He was formerly with Stryker Corp.(NYSE:SYK) directing operations of sales and marketing organizations for 21 distributorships for medical products including surgical instruments, orthopedic implants and endoscopy systems.

William Reeves, Lifeline's founder and president, said, "We are pleased and excited to have the caliber of experience Mr. Micheletti provides in areas the company needs in order to have an effective introduction and sales growth of the Mammoscope product line in the European market."

Micheletti, together with company representatives, are scheduled to attend the European Breast Cancer's Fourth Annual Conference in Hamburg, Germany, March 16-20, 2004. Lifeline will be featuring its Mammoscope and related products at the conference. Reeves noted that this conference will be attended by breast cancer specialists from all over the world. Holmes noted that he had received inquiries from Southeast Asia and China who have indicated they will be attending the conference and look forward to learning more about the Mammoscope.

Holmes noted that the company's efforts continue for FDA clearance for marketing the Mammoscope in the United States, and we are optimistic of a favorable development soon.

Lifeline's Web site address: www.lbti.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe," "expects," "projects," "forecasts," "intends," "will," "anticipated," "could" or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

---

They claim they have developed a revolutionary test that could detect breast cancer 6-10 years before any symptoms appear. Isn't LBTT's nipplescope supposed to do the same thing?

Thanks in advance.

RENO, Nev.--(BUSINESS WIRE)--Sept. 7, 2004--Lifeline Biotechnologies, Inc. (PINK: LBTT) today announced that the company has entered into a four-year contract with International Medical Consulting Group (IMCG) of Dallas, Texas, for its Chinese company, Shanghai Science Medical Equipment, Ltd., to distribute Lifeline's proprietary MastaScope(TM) Mammary Ductoscopy System in the People's Republic of China.
Carlo Micheletti, Lifeline's Director of International Sales and Marketing, made the announcement. The distribution agreement requires IMCG to purchase a minimum of 100 systems during the next four years. "This is a great step forward for Lifeline Biotechnologies' growth and development," said Micheletti. "To be able to participate in and promote our product into this huge market has positioned Lifeline to be at the forefront of a growing market. The mammary ductoscopy procedure is used to assist surgeons in the early visualization and detection of breast abnormalities in patients with Pathological Nipple Discharge (PND) and other breast irregularities."

IMCG's Shanghi subsidiary has been in business for more than 20 years and is currently staffed by some 125 professional sales representatives, sub dealerships and a proficient support staff, covering all the major cities in the People's Republic of China. IMCG and SSME have the capability of providing educational support to breast cancer surgeons and other medical professionals in the mammary ductoscopy procedure. "We believe this ability can result in the potential to capture a high percentage of the emerging Chinese market," said Micheletti.

Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's two divisions, Orthopedics Instruments and Cancer Detection technologies, each deal with cutting edge innovation to assist practicing physicians to deliver quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning Systems for assisting in the early detection of breast cancer and the Ovarian Scope for assisting in the early detection of ovarian cancer are continuing to be developed by the company. The Orthopedic division is the exclusive distributor for the Arthronet Shaver Blades in the US, Canada and Mexico and also the exclusive distributor for the Inion bioabsorable screw for the US and Canadian markets. More information is available at the company's website: www.lbti.com.

RENO, Nev., Sep 8, 2004 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc. (Pink Sheets:LBTT) today announced that the company's Pompano Beach office will be closed until later this week as a result of Hurricane Frances.

"Although we have no electric power, I'm pleased to report that there was no significant damage to our building, office, equipment or inventory. However, like millions of Floridians, we are without power, so our staff will all be working from home until power is restored," said Jonathan Reeves, President of Lifeline.

He noted that Lifeline is fortunate in that its operations are located throughout the country. "Our administrative, accounting, legal and financial operations are in Reno, Nevada, while our orthopedic division sales activities are centered in Michigan. Lifeline's Florida office serves as the company's operations (inventory, warehouse and shipping), technology and prototype development facility. Orders and shipments will be delayed until we are able to return to our Pompano Beach office later this week, at which time we will be able to catch-up."